|
| Status |
Public on Oct 17, 2021 |
| Title |
SY-1365, a covalent, first in-class CDK7 inhibitor for cancer treatment |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
Expression profiling by array
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Oct 17, 2018 |
| Last update date |
Oct 19, 2021 |
| Contact name |
Eric Olson |
| Organization name |
Syros Pharmaceuticals
|
| Street address |
480 Arsenal Street
|
| City |
Watertown |
| State/province |
MA |
| ZIP/Postal code |
02472 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
| GPL16043 |
GeneChip® PrimeView™ Human Gene Expression Array (with External spike-in RNAs) |
|
| Samples (32)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE121291 |
SY-1365, a covalent, first in-class CDK7 inhibitor for cancer treatment (microarray mRNA) |
| GSE121430 |
SY-1365, a covalent, first in-class CDK7 inhibitor for cancer treatment (ChIP-Seq) |
|
| Relations |
| BioProject |
PRJNA497304 |
Less...
More...